Numinus Wellness Inc. (NUMI:TSX) STA Research maintains Speculative Buy, .50 target

STA Research
by: STA Research
Numinus Wellness Inc.

STA Research assigned a  Speculative Buy rating on Numinus Wellness Inc., with a 12 month target of .50 cents on the stock price.

Based on the Numinus Wellness Inc. stock forecasts from 0 analysts, the average analyst target price for Numinus Wellness Inc. is not available over the next 12 months. Numinus Wellness Inc.’s average analyst rating is . Stock Target Advisor’s own stock analysis of Numinus Wellness Inc. is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Numinus Wellness Inc.’s stock price was CAD 0.28. Numinus Wellness Inc.’s stock price has changed by -0.07% over the past week, -0.12% over the past month and -70.74% over the last year.

Numinus Wellness Inc. offers solutions to develop and administer psychedelic-assisted psychotherapy, with the goal of transforming the landscape of mental health care. Salvation Botanicals and Numinus Health are the two business branches that make up this organisation. The Salvation Botanicals division provides services related to laboratories, including cultivation, analytical testing, product research and development, and ancillary services in the field of psychedelics, in addition to full suite testing and custom testing of cannabis. These services can be ordered through the division’s website. The Numinus Health division offers supporting therapies and technologies to heal, connect, and grow, with a primary focus on the treatment of mental health and substance misuse. This section also offers services for psychotherapy, counselling, neurofeedback, physiotherapy, and other therapies. In addition, this section provides practitioners with training, access to facilities, and a variety of other operational resources. The headquarters of the corporation may be found in Vancouver, which is located in Canada.

 

What we like:

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

 

What we don’t like:

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Leave a Reply

Your email address will not be published.